The ISN-ACT Global Trials Focus team has collected and published a new list of randomized research from nephrologists around the world for August 2020.
Each trial is reviewed in context and the risk of bias in seven key areas is assessed.
Highlight:
Allopurinol does not slow the progression of chronic kidney disease in patients with type 1 diabetes.
See the latest trials here.
Would you like to support equal access to nephrology research? Become an ISN Member
Kidney International® Outcomes From the International Society of Nephrology Hemolytic Uraemic Syndromes... read more
The High-impact Trials (HIT) sessions at WCN'25 promise exciting insights and... read more
This visual abstract was supported by Vera Therapeutics. Download Visual Abstract read more
The ISN congratulates its newest ISN-Named Fellows: Megan Borkum and Neeru Agarwal... read more
Download PDF A groundbreaking study led by ISN members as part of... read more
Two significant research studies were accepted as late-breaking clinical trials at... read more
Kidney International® A Randomized, Open-label Clinical Trial Examined the Effects of Canagliflozin... read more
The ISN PARADIGM meeting took place in Vancouver, BC, Canada, from... read more
The ISN recognizes the importance of global research initiatives in advancing... read more
The “ISN Global Kidney Trials Insights: A Guide for Everyone”... read more
